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Introduction: Traditional factors currently used for prognostic stratification do not always adequately predict
treatment response and disease evolution in advanced breast cancer patients. Therefore, the use of blood-based
markers, such as circulating tumor cells (CTCs), represents a promising complementary strategy for disease
monitoring. In this retrospective study, we explored the role of CTC counts as predictors of disease evolution in
breast cancer patients with limited metastatic dissemination.
Methods: A total of 492 advanced breast cancer patients who had a CTC count assessed by CellSearch prior to
starting a new line of systemic therapy were eligible for this analysis. Using the threshold of 5 CTCs/7.5 ml of blood,
pretreatment CTC counts were correlated in the overall population with metastatic site distribution, evaluated at
baseline and at the time of treatment failure, using Fisher’s exact test. Time to visceral progression and time to the
development of new metastatic lesions and sites were estimated in patients with nonvisceral metastases and with
single-site metastatic disease, respectively, by the Kaplan-Meier method. Survival times were compared between
groups according to pretreatment CTC count by logrank test.
Results: In the overall population, a pretreatment level ≥5 CTCs/7.5 ml was associated with an increased baseline
number of metastatic sites compared with <5 CTCs/7.5 ml (P = 0.0077). At the time of treatment failure, patients
with ≥5 CTCs/7.5 ml more frequently developed new metastatic lesions and sites compared with those with <5
CTCs/7.5 ml (development of new lesions: P = 0.0002; development of new sites: P = 0.0031). Among patients with
disease originally confined to nonvisceral sites, ≥5 CTCs/7.5 ml was associated with remarkably shorter time to
visceral metastases (P = 0.0021) and overall survival (P = 0.0006) compared with <5 CTCs/7.5 ml. In patients with
single-site metastatic disease, ≥5 CTCs/7.5 ml was associated with a significant reduction of the time to development
of new metastatic sites (P = 0.0051) and new lesions (P = 0.0002) and with worse overall survival (P = 0.0101).
Conclusion: Our results suggest that baseline CTC counts can be used as an early predictor of metastatic potential in
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Breast cancer mortality has decreased considerably over
the past two decades as a result of earlier diagnosis and
major treatment advances in the adjuvant and metastatic
settings [1]. Despite this progress, metastatic disease is
still largely considered an incurable condition, and 5-
year survival rates are <25% [1]. However, metastatic
breast cancer is a heterogeneous disease, and long-term
patient outcomes can be influenced by various biological
features, as well as by the extent and site of metastatic
disease. On the one hand, widespread visceral disease is
typically associated with symptoms leading to deterior-
ation of performance status and short survival [2]. On the
other hand, limited metastatic dissemination, primarily
confined to nonvisceral tissues, is more frequently associ-
ated with an indolent disease course and prolonged sur-
vival [3-5]. Nevertheless, the current standard assessment
of metastatic disease by morphological and functional im-
aging does not provide adequate information on tumor
biology and the presence of micrometastases, limiting the
possibility to predict tumor metastatic potential [3].
During the past decade, several techniques capable of
detecting and quantifying circulating tumor cells (CTCs)
in cancer patients have been developed [4,5]. It has been
proposed that subpopulations of CTCs with tumor-
initiating potential act as a central mediator of meta-
static dissemination, giving rise to the formation of
distant micrometastases, which subsequently generate
overt detectable and frequently measurable lesions [6].
In support of this theory, multiple studies have shown
that ≥5 CTCs/7.5 ml of blood, counted using the Cell-
Search System (Janssen Diagnostics, Raritan, NJ, USA)
and evaluated before starting systemic treatment, is associ-
ated with poor outcome in patients with metastatic breast
cancer [7-10]. In addition, high CTC counts are associated
with greater metastatic tumor burden, expressed as the
number of metastatic sites [8,11]. Importantly, despite this
association, the prognostic value of CTCs is independent
from the initial number of metastatic sites [8,11]. This
may suggest that the negative prognostic impact of high
CTC counts is not merely expression of the overt tumor
burden, but also may reflect higher biological aggressive-
ness and presence of undetectable micrometastatic dis-
ease, and ultimately may predict a greater tendency to
metastatic spread.
Therefore, we hypothesized that CTC counts, when
evaluated prior to starting systemic treatment, represent
an early marker of metastatic spread and are useful pri-
marily in patients with limited metastatic dissemination
and potentially eligible for locoregional treatments with
a curative intent [12-14]. To test our hypothesis, we ana-
lyzed the patterns of recurring metastatic dissemination
in patients with advanced breast cancer who had a CTC
count before starting a new line of systemic treatment.Methods
Study design
In this study, we conducted a retrospective analysis of a
preexisting database including 517 metastatic breast
cancer patients treated at The University of Texas MD
Anderson Cancer Center between September 2002 and
November 2009. All the patients had a CTC count using
the CellSearch System before starting a new line of sys-
temic treatment. From among the overall population,
492 women (95%) were selected for this analysis because
they had documented radiological follow-up. Eligible pa-
tients were categorized into two groups according to
baseline CTC counts using the well-established thresh-
old of 5 CTCs/7.5 ml of blood [7,15] (<5 CTCs/7.5 ml
versus ≥5 CTCs/7.5 ml of blood). Radiologic disease as-
sessments were performed in line with institutional
guidelines, and progression of disease (PD) was defined
according to the Response Evaluation Criteria In Solid
Tumors (RECIST) [16]. Reports based on radiologic as-
sessments performed in each patient after baseline CTC
evaluation were reviewed. The type of PD was recorded
and classified as appearance of new metastatic lesions,
either within the preexisting sites or in new metastatic
sites, or as dimensional increase of the preexisting le-
sions. These analyses were performed in the overall
population and selectively in patients with limited meta-
static dissemination at baseline, defined as disease con-
fined to nonvisceral organs or to a single organ. The
Institutional Review Board at MD Anderson Cancer
Center approved the study (DR10-0227) and granted a
waiver of informed consent, considering the retrospect-
ive nature of this analysis. Clinical data from the MD
Anderson Cancer Center’s electronic medical records
were collected by two physicians (AG and MG).
Isolation and enumeration of circulating tumor cells
Peripheral blood samples (7.5 ml) collected within
30 days before starting any systemic treatment were
drawn into CellSave tubes and processed within 72 hours
of collection. The standardized US Food and Drug
Administration–cleared CellSearch System was used to
isolate and count CTCs as previously reported [17].
CTCs were defined as nucleated, epithelial cell adhesion
molecule (EpCAM)–positive cells, expressing cytoplas-
mic cytokeratins 8, 18 and 19, but lacking expression of
the common leukocyte antigen CD45. All CTC evalua-
tions were performed by qualified personnel in a path-
ology laboratory certified in accordance with the Clinical
Laboratory Improvement Amendments.
Statistical analysis
The rate of new metastatic sites and new metastatic
lesions, the number of new metastatic sites developed at
the time of first PD (one or at least two) and the differences
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pared between the two CTC groups using Fisher’s exact
test. The number of metastatic sites present at baseline
(one, two or three or more) and the type of systemic
treatment were compared between the CTC groups
using Pearson’s χ2 test. Time to PD was defined as the
interval between baseline CTC count and PD or death.
Overall survival was defined as the time elapsed be-
tween initial CTC assessment and patient death. In pa-
tients with disease confined to a single organ, time to
new metastatic sites was calculated from baseline to the
appearance of new metastatic sites. In the same group,
time to new metastatic lesions indicated the interval be-
tween baseline CTC count and development of new
metastatic lesions, either in preexisting sites or at new
sites. Time to visceral disease was defined as the interval
between baseline and development of visceral metastases
in patients with disease initially confined to nonvisceral
organs. For the estimation of all of the aforementioned
survival times, in the absence of the specific event,
patients were censored at the date of the last follow-up.
Each survival time was estimated using the Kaplan-Meier
product limit method and compared between the CTC
groups (<5 CTCs/7.5 ml versus ≥5 CTCs/7.5 ml) by log-
rank test. Multivariate survival analysis was performed
using Cox’s regression. All the statistical analyses,Table 1 Baseline patient and tumor characteristics stratified b
Variable Overall, N (%) CT
Overall population 492 (100) 303
Treatment strategy
Systemic treatment only 467 (94.9) 286
Additional locoregional treatment 25 (5.1)a 16
Line of treatment
First 232 (47.2) 139
Second or later 260 (52.8) 164
Type of systemic treatment
Chemotherapy 376 (76.4) 218
Endocrine therapy 103 (20.9) 73
Other 13 (2.7) 12
Number of metastatic sites
1 146 (29.7) 104
2 145 (29.5) 89
≥3 201 (40.8) 110
Distribution of metastatic sites
Lymph nodes/soft tissuesb 58 (11.8) 48
Bonec 326 (66.2) 172
Viscerad 306 (62.2) 184
Braine 37 (7.5) 23
aAdditional locoregional treatments: surgery 15 (3.0%); radiation therapy 8 (1.6%); o
dVisceral organs (including brain) with or without other sites. eBrain with or withoutperformed using the PASW Statistical Analysis for Social
Sciences (SPSS) statistics software (SPSS, Chicago, IL,
USA), were two-sided, and P-values <0.05 were considered
statistically significant.
Results
Pretreatment circulating tumor cell counts correlated
with extent and site of metastatic disease at baseline
Baseline patient and tumor characteristics stratified by
CTC counts are reported in Table 1. Among the patient
sample, 303 (61.6%) had <5 CTCs/7.5 ml and 189
(38.4%) had ≥5 CTCs/7.5 ml. No significant difference in
terms of treatment strategy (systemic treatment only
versus additional locoregional treatment) and line of sys-
temic treatment was found between the CTC groups
(Table 1). Conversely, the type of systemic treatment sig-
nificantly differed, with a higher percentage of patients
receiving chemotherapy and a lower percentage receiv-
ing endocrine and other therapies in the group with ≥5
CTCs/7.5 ml compared with <5 CTCs/7.5 ml (P =
0.0041) (Table 1). The distribution of the immunohisto-
chemically defined tumor subtypes stratified by CTC
value was previously reported and did not show signifi-
cant differences between the CTC groups [8]. Also, in
line with previously published reports [8,18], high base-
line CTC counts were associated with greater metastaticy circulating tumor cell count
Cs <5/7.5 ml, n (%) CTCs ≥5/7.5 ml, n (%) P-value
(61.6) 189 (38.4) –
(94.7) 180 (95.2) ns
(5.3) 9 (4.8)
(45.9) 93 (49.2) ns
(54.1) 96 (50.8)
(71.9) 158 (83.6) 0.0041
(24.1) 30 (15.9)
(4.0) 1 (0.5)
(34.3) 42 (22.2) 0.0077
(29.4) 56 (29.6)
(36.3) 91 (48.2)
(15.8) 10 (5.3) 0.0003
(56.8) 154 (81.5) <0.0001
(60.7) 122 (64.6) ns
(7.6) 14 (7.4) ns
ther 2 (0.4%). bLymph nodes/soft tissue only. cBone with or without other sites.
other sites. CTCs, Circulating tumor cells; ns, Statistically nonsignificant.
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ment (Table 1). The percentage of cases with disease
confined to lymph nodes and/or soft tissues was signifi-
cantly higher in the group with low CTCs compared
with that of patients with high CTCs (Table 1).
Pretreatment circulating tumor cell counts correlated
with magnitude of metastatic dissemination at the time
of disease progression
At the time of this analysis, the median follow-up among
living patients was 32.2 months in the overall population
(33.4 months in the group with <5 CTCs/7.5 ml and
30.6 months in the group with ≥ 5 CTCs/7.5 ml). Among
the two groups, 264 patients (87.1%) with <5 CTCs/
7.5 ml and 178 (94.2%) with ≥5 CTCs/7.5 ml had experi-
enced PD before the last follow-up visit. Median times
to the first PD were 6.8 months (95% CI: 5.8 to
7.8 months) in subjects with <5 CTCs/7.5 ml and 5.9
(95% CI: 5.0 to 6.8 months) in those with ≥5 CTCs/
7.5 ml (P = 0.0059). The extent of metastatic spread oc-
curring at the time of the first PD after CTC assessment
was evaluated and correlated with the baseline CTC
counts. The development of new metastatic sites was
significantly more frequent among patients with ≥5
CTCs/7.5 ml compared to those with <5 CTCs/7.5 ml
(P = 0.0031) (Figure 1A). Similarly, the development of
new metastatic lesions, either within the preexisting sites
or in new metastatic sites, was more frequent in the
group of patients with ≥5 CTCs/7.5 ml (P = 0.0002)
(Figure 1B). In addition, the number of new metastatic
sites that developed at the time of first PD was signifi-
cantly higher in the patients with ≥5 CTCs/7.5 ml com-
pared to those with <5 CTCs/7.5 ml (P = 0.0083)
(Figure 1C). All of these findings translated into a marked
difference in long-term outcomes, with median overallFigure 1 Association of baseline circulating tumor cell counts with m
development of new metastatic sites (A) and new lesions (B) refer to the f
(N = 492), stratified by circulating tumor cell (CTC) count. (C) Number of ne
patients whose disease had progressed in new sites (n = 121), stratified bysurvival of 31.5 months (95% CI: 23.9 to 39.1 months) for
patients with <5 CTCs/7.5 ml versus 19.1 (95% CI: 15.9 to
22.3 months) for those with ≥5 CTCs/7.5 ml (P = 0.0001).
Pretreatment circulating tumor cell counts correlated
with visceral disease spread at the time of disease
progression
At the time of the first PD, similar to baseline, the fre-
quency of cases with metastatic disease confined to
lymph nodes and/or soft tissues was higher among pa-
tients with <5 CTCs/7.5 ml than in patients with ≥5
CTCs/7.5 ml (P = 0.0009) (Table 2). In addition, after
PD, the rate of visceral metastases became significantly
higher in the group of patients with ≥5 CTCs/7.5 ml
(P = 0.0114) (Table 2). Of note, we also observed a trend
for a higher frequency of brain metastases in patients
with ≥5 CTCs/7.5 ml (P = 0.0865) (Table 2).
To further assess the correlation between CTC counts
and visceral disease spread, we analyzed the patterns of
metastatic dissemination selectively in 186 patients
(37.8%) with disease initially confined to nonvisceral or-
gans. Of those, 119 (64%) had <5 CTCs/7.5 ml and 67
(36%) had ≥5 CTCs/7.5 ml. A total of 149 patients with
nonvisceral metastases experienced PD by the time of
their last visit. Among these patients, the development
of visceral metastases was significantly more frequent in
the group with ≥5 CTCs/7.5 ml compared to the group
with <5 CTCs/7.5 ml (40.7% versus 17.8%, respectively;
(P = 0.012) (Figure 2A). Also, the time to the develop-
ment of visceral disease was remarkably different be-
tween the CTC groups (42.1 months versus 15.9 months
in women with <5 CTCs/7.5 ml versus ≥5 CTCs/7.5 ml,
respectively; P = 0.0021) (Figure 2B). The multivariate
analysis demonstrated that the effect of CTC counts on
time to visceral disease was independent from otheretastatic spread in the overall population. (A) and (B) Rates of
irst progression of disease (PD) after baseline in the overall population
w metastatic sites that had developed by the first PD after baseline in
CTC count.
Table 2 Distribution of metastatic sites after treatment failure stratified by pretreatment circulating tumor cell counta
Overall, N (%) CTCs <5/7.5 ml, n (%) CTCs ≥5/7.5 ml, n (%) P-value
Lymph nodes/soft tissuesb 48 (9.8) 40 (13.2) 8 (4.2) 0.0009
Bonec 337 (68.5) 180 (59.4) 157 (83.1) <0.0001
Viscerad 344 (69.9) 199 (65.7) 145 (76.7) 0.0114
Braine 59 (12.0) 30 (9.9) 29 (15.3) 0.0865
aTreatment failure was defined as first disease progression after the baseline CTC evaluation. bLymph nodes/chest soft tissue only. cBone with or without other
sites. dVisceral organ (including brain) with or without other sites. eBrain with or without other sites.
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and human epidermal growth factor receptor 2 (HER2)
status, baseline number of metastatic sites and presence
of bone metastases (Additional file 1: Table S1). By the
time of the last follow-up visit, 53 (44.5%) of the 119 pa-
tients with <5 CTCs/7.5 ml and only 14 (20.9%) of the
67 with ≥5 CTCs/7.5 ml were free of visceral disease
(P = 0.0229). As expected, all of these findings were ac-
companied by a highly significant difference in overall
survival between the CTC groups (57.9 months for pa-
tients with CTCs <5 CTCs/7.5 ml versus 27.3 months
for those with ≥5 CTCs/7.5 ml; P = 0.0006).
Pretreatment circulating tumor cell counts correlated
with metastatic dissemination in patients with disease
originally confined to a single organ
The impact of high CTC counts on metastatic dissemin-
ation was also evaluated selectively in 146 patients
(29.7%) with disease originally confined to a single
organ. In this group, 104 women (71.2%) had <5 CTCs/
7.5 ml and 42 (28.8%) had ≥5 CTCs/7.5 ml at the base-
line evaluation (Table 3). No statistically significant dif-
ference was found between the two CTC groups in
terms of treatment strategy (systemic treatment alone or
systemic treatment plus additional locoregional treat-
ment) and type of systemic treatment (chemotherapy,
endocrine therapy or other). On the contrary, theFigure 2 Association of baseline circulating tumor cell counts with
disease (PD) occurring after baseline in 149 patients with disease initially
(CTC) count. Thirty-seven (19.9%) of the total of one hundred eighty-six
before the last follow-up visit. (B) and (C) Time to visceral disease (B) an
stratified by CTC count.anatomical distribution of the metastatic sites was sig-
nificantly different between the CTC groups, with bone
metastases more frequent in patients with ≥5 CTCs/
7.5 ml and soft-tissue/lymph node involvement more
frequent among those with <5 CTCs/7.5 ml (P = 0.023)
(Table 3). Median time to first PD was 12.2 months for
patients with <5 CTCs/7.5 ml and 7.1 months for those
with ≥5 CTCs/7.5 ml (P = 0.0373). Among the patients
who experienced PD, those with ≥5 CTCs/7.5 ml more
frequently developed new metastatic lesions, either
within the preexisting sites or in new metastatic sites,
compared to patients with <5 CTCs/7.5 ml (88.9%
versus 56.6%, respectively; P = 0.0031) (Figure 3A).
Moreover, the time to the development of new meta-
static sites was remarkably longer in patients with low
CTC counts compared to those with high counts
(40.2 months versus 15.9 months for patients with <5
CTCs/7.5 ml versus ≥5 CTCs/7.5 ml, respectively; P =
0.0051) (Figure 3B). Similarly, there was a striking dif-
ference in the length of time to development of new
metastatic lesions between the two CTC groups
(17.7 months for patients with <5 CTCs/7.5 ml versus
7.2 months for those with ≥5 CTCs/7.5 ml; P = 0.0002)
(Figure 3C). Importantly, the multivariate analysis
showed that these differences were not dependent on
other variables, including ER and HER2 status and
presence of visceral or bone metastases at baselinevisceral disease spread. (A) Types of the first progression of
confined to nonvisceral organs, stratified by circulating tumor cell
patients without baseline visceral metastases had not developed PD
d overall survival (C) in the 186 patients without visceral metastases,
Table 3 Baseline tumor features and treatments in patients with disease confined to a single organa
Variable Overall, N (%) CTCs <5/7.5 ml, n (%) CTCs ≥5/7.5 ml, n (%) P-value
Overall population 146 (100) 104 (71.2) 42 (28.8) –
HR status
Positive 99 (67.8) 67 (64.4) 32 (76.2) ns
Negative 47 (32.2) 37(35.6) 10 (23.8)
HER2 status
HER2 amplified/overexpressed 30 (20.6) 22 (21.2) 8 (19.1) ns
HER2 normal 116 (79.4) 82 (78.8) 34 (80.9)
Treatment strategy
Systemic treatment only 129 (88.4) 91 (87.5) 38 (90.5) ns
Additional locoregional treatment 17 (11.6)b 13 (12.5) 4 (9.5)
Type of systemic treatment
Chemotherapy 101 (69.2) 70 (67.3) 31 (73.8) ns
Endocrine therapy 41 (28.1) 31 (29.8) 10 (23.8)
Other 4 (2.7) 3 (2.9) 1 (2.4)
Distribution of metastatic sites
Lymph nodes/soft tissues 50 (34.2) 41 (39.4) 9 (21.4) 0.023
Bone 68 (46.6) 41 (39.4) 27 (64.3)
Viscera 28 (19.2) 22 (21.2) 6 (14.3)
aCTCs, Circulating tumor cells; HER2, Human epidermal growth factor receptor 2; HR, Hormone receptor; ns, Statistically nonsignificant. bAdditional locoregional
treatments: surgery in 12 patients (8.2%), radiation therapy in 4 patients (2.7%) and other for 1 patient (0.7%).
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findings translated to a significant difference in long-term
outcomes (overall survival: 40.3 months versus >60 months
for patients with ≥5 CTCs/7.5 ml versus <5 CTCs/7.5 ml,
respectively; P = 0.0101) (Figure 3D).
Discussion
Systemic metastatic spread represents the main cause of
breast cancer–related morbidity and death. Thus, for pa-
tients in the advanced stages of disease, it is critical to
improve treatment strategies that may affect not only
proliferation but also migration and invasion, important
features of the metastatic process. The traditional factors
currently used for prognostic stratification and treatment
decisions in the advanced stages of breast cancer, includ-
ing hormone receptor and HER2 status, site and extent
of metastatic burden, and length of disease-free interval,
often do not adequately predict treatment response and
disease evolution. In addition, treatment aggressiveness
is still debated in the presence of disease confined to
nonvisceral organs or asymptomatic visceral metastases.
In this scenario, the use of blood-based disease monitor-
ing, such as CTC assessment, may represent a comple-
mentary and informative strategy [19-23]. Recently, the
results of a prospective clinical trial confirmed the
strong prognostic value of CTCs in metastatic breast
cancer patients [10,24]. Moreover, a large pooled analysis
of individual patient data showed that adding CTCcount status to clinicopathological predictive models sig-
nificantly improved survival prognostication in advanced
breast cancer [24]. The results of our present study sug-
gest a novel role for CTCs as predictors of disease evolu-
tion in patients with advanced breast cancer, particularly
those with limited metastatic dissemination. We found
that pretreatment CTC counts ≥5/7.5 ml correlated with
greater metastatic dissemination at the time of treatment
failure, owing to more frequent appearance of new meta-
static lesions and sites. Also, the extent of the newly devel-
oped metastatic burden was greater in patients with ≥5
CTCs/7.5 ml compared with those with <5 CTCs/7.5 ml
[6]. We can hypothesize that elevated CTC numbers,
when observed prior to starting systemic treatment, may
reveal greater propensity to metastatic seeding and more
extensive micrometastatic disease and thus may function
as an early predictor of overt metastatic spread. This
further emphasizes the need to investigate the molecular
features of these cells in addition to their prognostic value.
Expectedly, CTC counts ≥5/7.5 ml were also associated
with lower frequency of disease confined to nonhemato-
genous metastatic sites, such as lymph nodes and soft
tissues. Importantly, among the patients with nonvisceral
metastases in our sample, ≥5 CTCs/7.5 ml predicted
higher risk of visceral progression. This finding could have
important clinical implications. Indeed, it is generally rec-
ommended that aggressive treatment strategies, such as
chemotherapy-based regimens, are needed in cases of
Figure 3 Association of baseline circulating tumor cell counts with metastatic spread in patients with single-site disease. (A) Type of
the first progression of disease (PD) occurring after baseline in 112 patients with single metastatic site disease, stratified by circulating tumor
cell (CTC) count. Thirty-four (23.3%) of the total one hundred forty-six patients with single-site disease had not developed PD before the last
follow-up visit. (B), (C) and (D) Time to new metastatic sites (B), time to new metastatic lesions (C) and overall survival (D) in the 146 patients
with single metastatic site disease, stratified by CTC count.
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ease [25,26]. On the basis of our results, it can be pro-
posed that pretreatment CTC counts may identify in
advance patients who have higher risk of developing wide-
spread visceral disease and consequently might benefit
from early administration of more aggressive systemic
treatments. Nevertheless, the retrospective nature of our
analysis suggests the need to prospectively validate the use
of CTCs as surrogate markers of metastatic potential, to-
gether with the investigation of new therapeutic strategies
aimed at targeting biological properties of CTCs, with the
goal of preventing or delaying PD and possibly improving
patient outcomes [27,28].
The link between micrometastatic disease and CTCs,
as well as their capability to predict overt metastatic
dissemination, may have important implications in
the clinical management of patients with single-sitemetastatic disease. Indeed, among patients with this
specific condition, pretreatment CTC counts ≥5/7.5 ml
were correlated with higher risk of developing new
metastatic sites and lesions at the time of treatment
failure. This may imply limited value of combined
therapeutic modalities that include local therapies in
patients with high CTC counts. However, 43% of
patients with single-site disease and <5 CTCs/7.5 ml
experienced dimensional increases in the preexisting
lesions when treatment resistance occurred. Hence,
pretreatment CTC counts <5/7.5 ml may identify a
subgroup of patients with single-organ disease who
have higher probability of maintaining this condition
for a longer time upon systemic treatment and for
whom locoregional ablative procedures, if feasible,
can contribute to symptom control and prolong sur-
vival [12-14].
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of CTC molecular profiling represent the main limita-
tions of this study, principally because molecular hetero-
geneity of CTCs may influence their role in metastatic
seeding. In particular, specific subpopulations of CTCs
undergoing molecular reprogramming known as the
epithelial-to-mesenchymal transition (EMT) [29,30]
process lose their epithelial differentiation and acquire
a mesenchymal phenotype, with increased invasion
capabilities and stemness properties [30,31]. The re-
sults of several studies suggest that CTCs with EMT
features are the major effectors of metastatic seeding
and are responsible for tumor progression [32-35].
Importantly, in the presence of the EMT process and
loss of epithelial markers, EpCAM-based isolation
methods, such as the CellSearch System, do not per-
form adequately. Thus, sensitive new strategies for
CTC isolation and analysis are needed in order to thor-
oughly use these cells for prediction of disease evolu-
tion [36,37].
Despite these limitations, our study is clinically rele-
vant because we propose, for the first time to our know-
ledge, a potential marker of disease spread in breast
cancer patients with limited metastatic dissemination.
Conclusion
Our findings suggest a new potential role for pretreat-
ment CTC counts as early predictors of metastatic po-
tential. This type of evaluation may be useful for
improved risk stratification in patients with nonvisceral
disease and single-organ metastatic involvement. Con-
sidering the limited number of patients evaluated in our
study, our results warrant larger studies based on CTC
enumeration and molecular profiling to develop novel
treatment decision tools for breast cancer patients with
limited metastatic dissemination.
Additional file
Additional file 1: Table S1. Multivariate analysis.
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